IMPACT OF COMORBIDITIES ON TIME IN THERAPEUTIC RANGE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
Jiyoon Choi(Bristol-Myers Squibb (United States)), Winnie W. Nelson(Janssen (United States)), Roger M. Mills(Janssen (Belgium)), Jeff Schein(Janssen (United States)), Peter Wildgoose(Janssen (United States)), C.V. Damaraju(Janssen (United States)), Larry E. Fields(Janssen (United States))
Cited by 4
Related Papers
Reflex Increase in Coronary Vascular Resistance in Patients with Ischemic Heart Disease
|New England Journal of Medicine|1976|480
Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure
|Journal of the American College of Cardiology|1999|323
Nitroprusside in Critically Ill Patients with Left Ventricular Dysfunction and Aortic Stenosis
|New England Journal of Medicine|2003|278
Impact of Intravenous Loop Diuretics on Outcomes of Patients Hospitalized with Acute Decompensated Heart Failure: Insights from the ADHERE Registry
|Cardiology|2008|263
Timing of Immunoreactive B-Type Natriuretic Peptide Levels and Treatment Delay in Acute Decompensated Heart Failure
|Journal of the American College of Cardiology|2008|206